Obiettivo Around 20% of all modern drugs are fluorinated organic molecules. During the recent years, however, pharmaceutical companies struggle to deliver novel drugs to the market, because of the lack of innovative practical reagents and reactions towards “drug-like” compounds. In this project, we will address this issue by discovering novel small fluorinating reagents - fluorinated diazoalkanes, - elaborate their practical reactions, and use this knowledge to develop alternative synthetic approaches to some known drugs (AS-136A, Celecoxib). Campo scientifico medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs Programma(i) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Argomento(i) MSCA-IF-2014-EF - Marie Skłodowska-Curie Individual Fellowships (IF-EF) Invito a presentare proposte H2020-MSCA-IF-2014 Vedi altri progetti per questo bando Meccanismo di finanziamento MSCA-IF-EF-ST - Standard EF Coordinatore ECOLE SUPERIEURE DE PHYSIQUE ET DECHIMIE INDUSTRIELLES DE LA VILLE DEPARIS Contribution nette de l'UE € 92 538,00 Indirizzo RUE VAUQUELIN 10 75231 Paris Francia Mostra sulla mappa Regione Ile-de-France Ile-de-France Paris Tipo di attività Higher or Secondary Education Establishments Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 92 538,00
